Trial Profile
A 2-Stage, Open-Label, Randomized, Single-Dose, Crossover Study to Determine the Effect of the Timing of a Meal on the Pharmacokinetics of Entinostat in Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Aug 2018
Price :
$35
*
At a glance
- Drugs Entinostat (Primary)
- Indications Breast cancer; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Follicular lymphoma; Hodgkin's disease; Leukaemia; Malignant melanoma; Neuroendocrine tumours; Non-small cell lung cancer; Renal cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Syndax Pharmaceuticals
- 14 Aug 2018 Status changed from not yet recruiting to completed.
- 12 Oct 2016 New trial record